TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The FDA approved AbbVie’s once-daily pill Juvmo (tavapadon) on Sept. 25, 2026, for treating Parkinson’s symptoms. It can be used alone in early Parkinson’s or added to other medication in later stages; AbbVie expects U.S. availability in October. The trials showed motor-symptom benefits, but were not long enough to determine whether the drug reduces impulse-control problems.
The U.S. Food and Drug Administration approved Juvmo, AbbVie’s once-daily pill for Parkinson’s symptoms, on Sept. 25, clearing it for use alone in early Parkinson’s and alongside existing medication in later stages. The decision adds a treatment option intended to improve motor symptoms and, when used as an add-on, extend the time other medication is working.
Juvmo, known as tavapadon during clinical trials, was evaluated in three randomized, placebo-controlled Phase 3 trials lasting 26 weeks, with more than 1,300 participants overall, according to the report. Two trials studied the pill as a standalone treatment and found improvements in motor symptoms. Reported side effects included nausea and headache, described as mild to moderate in the report.
A third trial tested Juvmo as an add-on to existing treatment. It found that the drug helped extend “on time,” when Parkinson’s medication is working, and reduce “off time,” when its effects wear off. The report does not provide numerical effect sizes or detailed trial results, so the size of those changes cannot be assessed from the available information.
AbbVie expects Juvmo to be available in the United States in October 2026. The report does not give a price, a specific launch date, or further details about distribution.
A Once-Daily Option for Parkinson’s
Many existing Parkinson’s medicines need to be taken several times a day, and treatment can involve managing motor symptoms alongside side effects. A once-daily pill approved for both standalone and add-on use gives clinicians another option to consider as patients’ treatment needs change. The approval could also matter to people who have difficulty keeping up with multiple daily doses, although the supplied report does not describe adherence results for Juvmo.
The treatment’s potential role should be viewed within the limits of the reported evidence. The Phase 3 trials showed motor-symptom improvements over 26 weeks, but the available account does not establish how well those benefits persist over longer periods or how Juvmo compares directly with other treatments.
How Juvmo Targets Dopamine
Parkinson’s involves the loss of neurons that produce dopamine, a chemical involved in movement. The report describes many existing dopamine agonists as mimicking dopamine by activating D2 and D3 receptors. These treatments can help motor symptoms, but their use is associated with side effects that may affect treatment decisions.
Juvmo works differently, according to the report: it activates D1 and D5 receptors. The FDA approval covers use as a standalone treatment for early Parkinson’s symptoms and as an add-on in later stages. The distinction concerns the receptor targets; it does not, by itself, establish that Juvmo has fewer side effects for every patient.
““It’s not a huge game-changer, but definitely a nice additional tool to have.””
— Dr. Bryan Ho, director of the Movement Disorders Program at Tufts Medical Center, in a previous interview with Being Patient
Long-Term Risks Need More Study
The reported trials lasted 26 weeks, and the account says they were not long enough to determine whether Juvmo reduces the risk of impulse-control problems. Such problems can include behaviors such as gambling, according to the report. Whether the drug changes that risk remains unclear.
The supplied source does not include detailed trial data, long-term outcomes, a direct comparison with other medicines, or information about the drug’s price. It also does not specify which patients may be most likely to benefit or experience side effects. Those questions cannot be answered from the approval announcement and trial summary alone.
U.S. Launch Expected in October
AbbVie expects Juvmo to reach the U.S. market in October 2026. Further details about its availability, cost, and prescribing information may clarify how clinicians and patients can access it. Until longer-term evidence is available, the extent of any effect on impulse-control risks remains unresolved.
Key Questions
What is Juvmo?
Juvmo is AbbVie’s once-daily pill for treating Parkinson’s symptoms. Its clinical-trial name was tavapadon.
How did the FDA approve it for use?
The FDA approved Juvmo as a standalone treatment in early Parkinson’s and as an add-on to existing medication in later stages.
What did the Phase 3 trials find?
In three 26-week trials involving more than 1,300 participants, the standalone-treatment trials found motor-symptom improvements, while the add-on trial found longer “on time” and less “off time,” according to the report.
When is Juvmo expected to be available in the U.S.?
AbbVie expects U.S. availability in October 2026. The report does not provide a specific launch date.
Is it known whether Juvmo reduces impulse-control problems?
No. The reported trials were not long enough to determine whether Juvmo reduces the risk of impulse-control problems.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
